Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orchard Therapeutics (NASDAQ: ORTX) and Epizyme (NASDAQ: EPZM)
10:22am, Wednesday, 01'st Apr 2020
Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on Orchard Therapeutics (
ORTX
–
Research Report
) and Epizyme (
EPZM
–
Research Report
).
Orchard The
Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT
05:43am, Wednesday, 01'st Apr 2020
Q4 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Given Average Rating of "Buy" by Brokerages
05:36am, Wednesday, 01'st Apr 2020
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has been assigned an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat.com reports.
Cannabis Central: Sector Improved Marginally Tuesday (-1.3%); Here Are The Top Winners 7 Losers
04:59am, Wednesday, 01'st Apr 2020
Today's article identifies the 6 non-penny stocks in the sector that increased by a minimum of 5%, the 6 that declined in excess of 5% and 6 of the remaining stocks that warrant mentioning.
Edited Transcript of CRBP earnings conference call or presentation 12-Mar-20 12:30pm GMT
01:20am, Wednesday, 01'st Apr 2020
Q4 2019 Corbus Pharmaceuticals Holdings Inc Earnings Call
Avenue Therapeutics (ATXI) Gets a Buy Rating from Oppenheimer
04:32pm, Tuesday, 31'st Mar 2020
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Avenue Therapeutics (ATXI), with a price target of $12.00. The
Avenue Therapeutics (ATXI) Gets a Buy Rating from Oppenheimer
04:32pm, Tuesday, 31'st Mar 2020
In a report released today,
Leland Gershell
from Oppenheimer maintained a
Buy
rating on Avenue Therapeutics (
ATXI
–
Research Report
), with a price target of
$12.00
. The company’s shares closed
What Made Oppenheimer Upgrade Amarin's Stock?
11:10am, Tuesday, 31'st Mar 2020
Amarin (AMRN) received a Hold rating from Oppenheimer analyst Leland Gershell today. The company's shares closed last Monday at $13.58. According to
What Made Oppenheimer Upgrade Amarin’s Stock?
11:10am, Tuesday, 31'st Mar 2020
Amarin (
AMRN
–
Research Report
) received a
Hold
rating
from Oppenheimer analyst
Leland Gershell
today. The company’s shares closed last Monday at $13.58.
According to
TipRanks.com
, Gershell is
Cannabis Central: Sector Declined 2.9% On Monday With Hexo & Tilray Each Declining 28%
09:01am, Tuesday, 31'st Mar 2020
Monday saw a 2.9% decline in the 37 non-penny pot stocks on the heels of a 3.0% decline on Friday with 10 advancing and 27 declining. The losers were Hexo (-28.1%), Tilray (-27.4%) and MediPharm (-17.
Cannabis Stock Gainers And Losers From March 30, 2020
08:37pm, Monday, 30'th Mar 2020
Gainers
VIVO Cannabis (OTC: VVCIF) stocks closed up 23.57% at $0.18
Meridian Bioscience (NASDAQ:) stocks closed up 13.37% at $7.97
The Flowr (OTC: FLWPF) stocks...
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Buy Rating from Analysts at Nomura
10:32am, Monday, 30'th Mar 2020
Nomura began coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP) in a report published on Thursday morning, Benzinga reports. The firm issued a buy rating and a $112.00 price objective on the b
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by BidaskClub to Buy
06:54am, Monday, 30'th Mar 2020
Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, BidAskClub reports. A n
Corbus Pharmaceuticals (NASDAQ:CRBP) Trading Down 6.8%
10:20am, Sunday, 29'th Mar 2020
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)’s stock price traded down 6.8% during mid-day trading on Friday . The company traded as low as $5.20 and last traded at $5.20, 719,567 shares were t
ProShare Advisors LLC Decreases Stock Position in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)
10:20am, Saturday, 28'th Mar 2020
ProShare Advisors LLC cut its stake in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities
